Document is current
Any future updates will be listed below
-
Authors
Wixner, Jonas
Dispenzieri, Angela
Amass, Leslie
Carlsson, Martin
Riley, Steve
Powers, Evan
Kelly, Jeffery W.
,
Cariou, Eve
Costello, Jose Gonzalez
Grogan, Martha
Kristen, Arnt V.
Slosky, David
de BarrosCorreia, Edileide
Moreno, Juan Gonzalez
Luigetti, Marco
Waddington-Cruz, Marcia
Conceicao, Isabel
Emden, Michele
Kim, Darae
Freimer, Miriam
Warner, Alberta
Pavia, Pablo Garcia
Quan, Dianna
Diemberger, Igor
Nienhuis, Hans
Miller, Edward
Lenihan, Daniel
Praktiknjo, Michael
Tan, Cheng Yin
Mohty, Dania
Zivkovic, Sasa
Badarin, Firas Al
Tournev, Ivailo
Plante-Bordeneuve, Violaine
Ueda, Mitsuharu
Briseno, Maria Alejandra Gonzalez Duarte
Mueller, Christopher
Fine, Nowell
Brunkhorst, Robert
Adams, David
Azevedo, Olga
Chao, Chi-Chao
Nicolau, Jose Nativi
Tallaj, Jose
Torrón, Roberto Fernandéz
Inamo, Jocelyn
Badelita, Sorina
Polydefkis, Michael
Sarswat, Nitasha
Tauras, James
Coelho, Teresa
Salutto, Valeria Lujan
Delgado, Diego
Tschoepe, Carsten
Beamud, Francisco Munoz
Cirami, Calogero Lino
Gottlieb, Stephen
Drachman, Brian
Ventura, Hector
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00628745 at ClinicalTrials.govDocuments that mention this clinical trial
A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey
https://doi.org/10.1007/s40120-021-00267-y
Survival in a Contemporary, Real-World Cohort of Patients with Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: An Analysis from THAOS
https://doi.org/10.1007/s40119-025-00421-9
A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy
https://doi.org/10.1080/13506129.2019.1643714
The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology
https://doi.org/10.1185/03007995.2012.754349
THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis
https://doi.org/10.1185/03007995.2012.754348
Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
https://doi.org/10.1007/s40119-022-00265-7
Phenotypic Differences of Glu89Gln Genotype in ATTR Amyloidosis From Endemic Loci: Update From THAOS
https://doi.org/10.1007/s40119-021-00226-6
Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey
https://doi.org/10.1007/s40119-023-00344-3
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 16 April 2025
Accepted: 13 June 2025
First Online: 9 July 2025
Declarations
:
: Jonas Wixner reports consulting fees and travel support for lectures and advisory boards from Alnylam and Pfizer and consulting fees from Akcea, AstraZeneca, Bayer and Intellia. Angela Dispenzieri reports research grants from Alnylam, Celgene, Janssen, Millennium, and Pfizer; funding for meeting expenses (travel) from Pfizer; and attending advisory boards for Akcea and Intellia. Leslie Amass, Martin Carlsson, and Steve Riley are employees of Pfizer. Evan Powers receives royalty payments from tafamidis sales. Jeffery W Kelly receives royalty payments from tafamidis sales and reports consulting fees and travel support for lectures from Pfizer and attending advistory boards for Pfizer.
: All THAOS sites received ethical or institutional review board approval before patient enrollment, and all patients provided written informed consent. The ethics committee that approved the study at the lead author’s institution was Regionala etikprövningsnämnden i Umeå. All other committees are listed in Supplementary Table . The study followed the Good Pharmacoepidemiology Practice guidelines and the principles of the Declaration of Helsinki.
